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Abstract 
Introduction. Escalating medical costs continue to be an issue facing contemporary medicine. 
One factor contributing to this escalation may be physicians’ knowledge of medication costs. As 
physicians increasingly face opportunities to treat a variety of symptoms and conditions in a 
single patient, including co-morbid psychiatric disorders or complications, accurate knowledge 
of medication costs becomes increasingly important.  
Methods. Resident and attending physicians (N = 16) across the disciplines of internal medicine, 
psychiatry, and combined internal medicine/psychiatry from a large, mid-western medical school 
were surveyed on the costs of several medications that are used to manage physical and 
psychiatric symptoms.  
Results. Differences were found in the perceived estimated cost of medications among 
practitioners particularly with specialty internal medicine training as compared to those with 
additional psychiatric training/experience. Trends also were noted across practitioners with 
psychiatric and internal medicine/psychiatry training. 
Conclusions. The breadth of training and experience can affect accuracy in estimating 
anticipated costs of medication regimens.  
KS J Med 2013; 6(3):89-93. 
 
 
Introduction 
The major factors contributing to high 
and rapidly growing health care costs remain 
an important issue facing the modern 
practice of medicine.
1
 Some factors 
contribute to the high level of spending, 
others drive growth, and some play a role in 
both. Provider knowledge of various 
treatments is paramount in curbing these 
expenses.  
Physicians have inadequate knowledge 
of medication costs.
2
 Furthermore, medical 
schools generally do not teach costs of 
treatments to students. This information is 
learned most often during practice 
contributing to rising medical treatment 
expenditures.
3
 With healthcare costs 
 
climbing, physicians should have an 
understanding about the general costs of the 
medications that they prescribe. To 
implement cost-saving changes, the 
deficiency must be recognized.
4
  
Until recently, most schools included 
little information on financial factors in 
medical education, such as insurance 
coverage and how treatment costs affect 
patients’ behavior. Once recognized, schools 
can have a positive impact on prescribing 
patterns by providing information regarding 
commonly used prescriptions. Okie
5
 
reported an interactive teaching conference 
with distribution of a pocket guide listing 
the average wholesale prices of over 100 
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medications commonly used in primary 
care. Appropriately, this intervention was 
associated with some change in prescribing 
habits. Without such interventions and 
insights, physicians may practice with little 
sense of how to make the most cost-
effective choices for patients.
1
 
Given the scope of issues treated and 
patients served, some physicians may be 
more inclined to appreciate financial aspects 
of recommended care provided they are 
educated on the general costs of medications 
being prescribed. Internists and psychiatrists 
may be susceptible to making errors in the 
estimation of medication costs despite ample 
opportunity to manage a variety of issues 
(psychiatric or otherwise).
6
  
In the light of the ever-growing role of 
psychiatrists in general medical care (e.g., 
consultation services) and areas of combined 
specialization (e.g., dual training in internal 
medicine and psychiatry), further assess-
ment regarding the knowledge of medication 
costs has an incrementally important role in 
psychiatry. Given these factors, the present 
study examined this knowledge of 
psychiatric medication costs by practitioners 
and residents from the areas of internal 
medicine, psychiatry, and combined internal 
medicine/psychiatry. 
 
Methods 
This study was approved by the 
Institutional Review Board at the University 
of Kansas Medical Center.  
Participants. Sixteen anonymous re-
spondents were comprised from a sample of 
1) psychiatry residents, 2) attending psychia-
trists, 3) internal medicine residents, 4) 
attending internists, 5) residents in internal 
medicine/psychiatry, and 6) attending physi-
cians with board eligibility/certification in 
internal medicine and psychiatry. Residents 
were at various years of training across 
programs. Attending physicians varied in 
age and level of experience. 
Procedures. The participants were given 
a 17-question survey administered through 
SurveyMonkey
®
 (an internet survey 
website). The questionnaire was divided into 
six groups as defined in the subject selection 
section. The responses for each group were 
compiled collectively and compared to the 
true cost of medications, as referenced from 
national pharmacies. Participants completed 
the survey over a two-week period (6 
psychiatry residents, 1 attending 
psychiatrist, 2 attending physicians with 
board eligibility/certification in internal 
medicine and psychiatry, 2 internal 
medicine/psychiatry residents, 3 internal 
medicine residents, and 2 attending 
internists).  
The survey assessed estimated cost of a 
variety of commonly-used psychiatric 
medications including: tricyclic anti-
depressants (TCAs), selective serotonin 
reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), 
and atypical antipsychotics at varying doses 
(Lexapro
®
, Abilify
®
, Welbutrin
®
, Celexa
®
, 
Cymbalta
®
, Effexor
®
, Prozac
®
, Remeron
®
, 
Pamelor
®
, Tofranil
®
, Paxil
®
, and Xanax
®
). 
All medications were referred to as 
“generic” to blind expectations concerning 
medication costs. Dosages ranged from “5 
mg” to “75 mg” under the prescribed 
duration of “a month” when participants 
were asked to anticipate prescription costs. 
Perceived costs were compared against 
actual costs averaged from six local 
pharmacies.    
Data analysis. Data were averaged and 
compiled to examine potential group 
differences in perception of psychiatric 
medication costs.  
 
Results 
Average group differences were 
reviewed to estimate perception of 
medication costs. The perceived cost of 
Tofranil
®
 among individuals with internal 
Kansas Journal of Medicine 2013                          Psychiatric Medication Costs 
 
91 
 
medicine training suggested a higher 
perceived cost of this medication in clinical 
practice relative to practitioners in 
psychiatry. Practitioners with internal 
medicine training estimated Paxil
®
 and 
Celexa
®
 to be relatively more expensive 
compared to practitioners with psychiatry 
training. Abilify
®
 was estimated to be less 
expensive in this group compared to 
psychiatry practitioners who estimated this 
medication to be more costly. These effects 
are described in Figure 1. Providers with 
combined training (e.g., internal medicine 
and psychiatry) tended to be more accurate 
in estimating psychiatric medication costs 
than physicians with primarily internal 
medicine training. 
 
Figure 1. Summary of estimated medication costs across disciplines. 
Discussion
Although the study sample is small, the 
resultant data suggested that differences 
exist in perception of medication costs that 
vary with relation to medical training and 
expertise. Examination of results suggested 
differences among groups of practitioners 
(psychiatry, internal medicine, and 
combined internal medicine/psychiatry) 
across a range of training levels.  This was 
driven by a tendency for Tofranil
®
 (a TCA 
primarily used for depression and chronic 
pain) to be rated as more expensive among 
physicians with only internal medicine 
training relative to physicians with training 
in psychiatry or combined internal 
medicine/psychiatry training. Additionally, 
trends were appreciable for Paxil
®
, Celexa
®
, 
and Abilify
®
 across providers, suggesting 
that physicians with internal medicine view 
Paxil
®
 and Celexa
®
 as expensive, while 
viewing Abilify
®
 as inexpensive relative to 
their colleagues in psychiatry. In noting 
these differences in estimated medication 
costs across providers, our findings were 
consistent with previous studies.  
Hoffman et al.
1 examined physicians’ 
and pharmacists’ knowledge of non-
steroidal anti-inflammatory drugs 
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(NSAIDs). They reported that although 
physicians overwhelmingly viewed cost as 
an important factor in prescribing 
medication (81% of respondents), only 75% 
of physicians correctly estimated the price of 
half of the medications surveyed; 65% of 
medication costs were underestimated. In 
this light, Hoffman and colleagues
1
 
concluded that practitioners could benefit 
from further knowledge to improve accuracy 
and avoid under-estimation of medication 
costs.  
Our work extended this study, as prior 
research has not targeted the costs of 
psychiatric medications. In this study, over- 
and under-estimation of psychiatric 
medication costs occurred in particular 
among non-psychiatry specialists. Addition-
ally, providers with combined training 
tended to be slightly more accurate across 
the medications surveyed.  
There are many possible causes for the 
differences in provider response. One 
primary reason may be familiarity with these 
medications. Physicians with training in 
both internal medicine and psychiatry may 
have greater opportunity to learn about 
medications that can have applications 
across disciplines (e.g., managing pain, 
depression, and aiding sleep) due to the 
clinical issues that are faced. Greater 
exposure to medication costs can affect 
prescription patterns.  
Recently, Cooke
4 
commented that when 
providers are made aware of such issues, 
they are quick to learn and respond to the 
costs of medications. Similar observations 
have been noted across clinical and training 
settings.
5
 These observations demonstrate 
that physicians can benefit from this type of 
education at any level of training. However, 
given a relative lack of education on 
medication costs provided in medical 
schools,
3
 alongside the responsiveness 
physicians have to such education,
4-5
 
increasing this insight in a wide range of 
medical environments may be beneficial.  
Increased training should yield cost 
reductions in healthcare by preventing 
underestimation of medication costs in the 
first place.
1
 If providers have greater 
exposure and knowledge of medication 
costs, they will be in a better position to 
consider treatment costs when caring for a 
diverse patient population. Given the 
increasing treatment of psychiatric issues in 
general medicine, educating students and 
practitioners on psychiatric medical costs 
will become more important.  
Another consideration is the increasing 
access to information concerning 
medication. The present survey was 
administered with no constraints in regards 
to use of standard references. As society 
modernizes and access to information is 
increasingly more available, a majority of 
practitioners and residents could access 
programs, reliably and easily, that give drug 
information via a variety of handheld 
devices, applications, and computer 
programs. In many cases, manufacturing/ 
pricing information can be provided for each 
medication which is generally accurate and 
used frequently by residents and medical 
providers as a cost reference while 
prescribing. It is unclear if any of our 
participants utilized this information while 
completing the survey.  
Medical schools, residency programs, 
attending physicians, and private 
practitioners should seek up-to-date 
information concerning medicine costs in 
the best interest of patient care and potential 
reduction of in healthcare costs.
 
References 
1 Hoffman J, Barefield FA, Ramamurthy S. 
A survey of physician knowledge of drug  
 
 
costs. J Pain Symptom Manage 1995; 
10(6):432-435. PMID: 7561225. 
Kansas Journal of Medicine 2013                          Psychiatric Medication Costs 
 
93 
 
2 Korn HM, Reichert S, Simon T, Halm EA. 
Improving physicians’ knowledge  of the 
costs of common medications and 
willingness to consider costs when 
prescribing. J Gen Intern Med 2003; 
18(1):31-37. PMID: 12534761. 
3 Doebbeling CC, Pitkin AK, Malis R, 
Yates WR. Combined internal medicine-
psychiatry and family medicine-psychiatry 
training programs, 1999-2000: Program 
directors’ perspectives. Acad Med 2001; 
76(12):1247-1252. PMID: 11739052. 
4 Cooke M. Cost consciousness in patient 
care - What is medical education’s 
responsibility? N Engl J Med 2010; 
362(14):1253-1255. PMID: 20357275. 
5 Okie S. Teaching physicians the price of 
care. The New York Times. 2010. 
Accessed at: http://www.nytimes.com/ 
2010/05/04/health/04cost.html?pagewante
d=all. 
6 Raynes NV. Involving residents in quality 
specification. Ageing Soc 1988; 18(1):65-
78.  
 
Keywords: drug costs, psychiatry, internal 
medicine 
